Kim Fabiano Marquart

Nerai Bioscience

This project combines artificial intelligence with high-throughput directed evolution to engineer customized CRISPR gene-editing tools that can target disease mutations currently unreachable with existing methods. With initial applications in rare metabolic and liver disorders such as citrullinemia type I and phenylketonuria, the work aims to expand patient access to first-in-class genome medicines.